{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:49Z","timestamp":1789628509888,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Epilepsy is one of the most prevalent neurological disorders, affecting approximately 1% of the population, with one-third of patients developing drug-resistant epilepsy (DRE). In addition, metabolic syndrome (MetS), through inflammation and oxidative stress mechanisms, may influence epilepsy outcomes. The main objective of the current study is to determine the prevalence of MetS among patients with epilepsy (PWE) and evaluate its association with DRE. This cross-sectional study was conducted between March and October 2024 at a regional hospital in Tehran, involving 180 PWE aged 18 to 70 years. Participants were classified into well-controlled epilepsy and DRE groups based on the International League Against Epilepsy criteria. MetS was also diagnosed using the International Diabetes Federation guidelines. Data were analyzed using SPSS software, which illustrated that MetS was present in 33.8% of participants, with a significantly higher prevalence in well-controlled epilepsy patients (47.7%) compared with those with DRE (20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001), and it played a role in predicting response to treatment in PWE. Furthermore, body mass index, waist circumference, and blood pressure were significantly higher in the well-controlled group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.012 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.007, respectively). MetS was more prevalent in well-controlled epilepsy patients and was associated with a decreased risk of DRE. However, further research is needed to explore the relationship between MetS and DRE.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050264","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:26Z","timestamp":1787331986000},"page":"e50264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is there an association between metabolic syndrome and drug resistance in patients with epilepsy?"],"prefix":"10.1097","volume":"105","author":[{"given":"Afshan","family":"Davari","sequence":"first","affiliation":[{"name":"Medical Colleges, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1275-1138","authenticated-orcid":false,"given":"Amir Reza","family":"Bahadori","sequence":"additional","affiliation":[{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Imeni Kashan","sequence":"additional","affiliation":[{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"School of Medicine, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Sheikhvatan","sequence":"additional","affiliation":[{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Medical Biology and Genetics Department, Okan University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ranji","sequence":"additional","affiliation":[{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Shafiee","sequence":"additional","affiliation":[{"name":"Mazandaran University of Medical Sciences, Sari, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-9760","authenticated-orcid":false,"given":"Abbas","family":"Tafakhori","sequence":"additional","affiliation":[{"name":"Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies.","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis.","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"111135","DOI":"10.1016\/j.yebeh.2026.111135","article-title":"Prevalence of drug-resistant epilepsy in low and middle income countries: a systematic review and meta-analysis.","volume":"183","author":"Bahadori","year":"2026","journal-title":"Epilepsy Behav"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology.","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cca.2019.06.019","article-title":"Metabolic syndrome is an inflammatory disorder: a conspiracy between adipose tissue and phagocytes.","volume":"496","author":"Reddy","year":"2019","journal-title":"Clin Chim Acta"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"e15239","DOI":"10.14814\/phy2.15239","article-title":"The role of astrocytes in epileptic disorders.","volume":"10","author":"Hayatdavoudi","year":"2022","journal-title":"Physiol Rep"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.yebeh.2008.06.012","article-title":"Patient-perceived risk associated with epilepsy and its medication treatment.","volume":"13","author":"Kucukarslan","year":"2008","journal-title":"Epilepsy Behav"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2021.07.019","article-title":"Associations of overweight and obesity with drug-resistant epilepsy.","volume":"92","author":"Chen","year":"2021","journal-title":"Seizure"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/aam.aam_139_22","article-title":"Obesity and metabolic syndrome in patients with epilepsy, their relation with epilepsy control.","volume":"22","author":"Nazish","year":"2023","journal-title":"Ann Afr Med"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fncel.2018.00335","article-title":"Bioenergetic mechanisms of seizure control.","volume":"12","author":"Kov\u00e1cs","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13679-016-0237-4","article-title":"Changes in energy expenditure with weight gain and weight loss in humans.","volume":"5","author":"M\u00fcller","year":"2016","journal-title":"Curr Obes Rep"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"107296","DOI":"10.1016\/j.yebeh.2020.107296","article-title":"Metabolic syndrome and obstructive sleep apnea syndrome among patients with epilepsy on monotherapy.","volume":"111","author":"S\u00f6ylemez","year":"2020","journal-title":"Epilepsy Behav"},{"key":"R17-20260917","first-page":"1","article-title":"Prevalence and risk factors for the metabolic syndrome among patients with epilepsy attending a neuropsychiatric hospital in Kigali, Rwanda.","volume":"6","author":"Ndayambaje","year":"2021","journal-title":"Int J Adv Sci Res Manag"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"e0279580","DOI":"10.1371\/journal.pone.0279580","article-title":"Metabolic syndrome and its associated factors among epileptic patients at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia; a hospital-based comparative cross-sectional study.","volume":"17","author":"Beyene Kassaw","year":"2022","journal-title":"PLoS One"},{"key":"R19-20260917","first-page":"41350","article-title":"Non-HDL cholesterol, obesity, and metabolic syndrome in epileptic patients.","volume":"24","author":"Khuda","year":"2022","journal-title":"Prim Care Companion CNS Disord"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"106992","DOI":"10.1016\/j.yebeh.2020.106992","article-title":"Metabolic syndrome in people with epilepsy.","volume":"106","author":"Vooturi","year":"2020","journal-title":"Epilepsy Behav"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"143924","DOI":"10.1016\/j.gene.2019.06.014","article-title":"Involvement of MnSOD Ala16Val polymorphism in epilepsy: a relationship with seizure type, inflammation, and metabolic syndrome.","volume":"711","author":"Kegler","year":"2019","journal-title":"Gene"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s11064-023-03891-2","article-title":"Regulatory basis of adipokines leptin and adiponectin in epilepsy: from signaling pathways to glucose metabolism.","volume":"48","author":"Shan","year":"2023","journal-title":"Neurochem Res"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12974-025-03553-w","article-title":"The interplay between metabolism and neuroinflammation in epilepsy: mechanisms and therapeutic perspectives.","volume":"22","author":"Xu","year":"2025","journal-title":"J Neuroinflammation"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"110295","DOI":"10.1016\/j.yebeh.2025.110295","article-title":"Investigation of the relationship between body mass index and epilepsy.","volume":"165","author":"Li","year":"2025","journal-title":"Epilepsy Behav"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/biomedicines11051499","article-title":"Valproate-induced metabolic syndrome.","volume":"11","author":"Shnayder","year":"2023","journal-title":"Biomedicines"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jocn.2010.01.045","article-title":"Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment.","volume":"17","author":"Genc","year":"2010","journal-title":"J Clin Neurosci"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.410430406","article-title":"Valproate, lamotrigine, and insulin\u2010mediated risks in women with epilepsy.","volume":"43","author":"Isoj\u00e4rvi","year":"1998","journal-title":"Ann Neurol"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"248","DOI":"10.25130\/tjphs.2012.8.2.14.248.255","article-title":"Effects of carbamazepine on blood pressure, serum glucose concentration, lipid profile and prevalence of metabolic syndrome in epileptic patients.","volume":"8","author":"Mahmood","year":"2012","journal-title":"Tikrit J Pharm Sci"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/oby.24362","article-title":"Long\u2010term medication\u2010induced weight change across common antiseizure medications: a target trial emulation study.","volume":"33","author":"Yu","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40263-025-01231-2","article-title":"Effects of antiseizure medications on lipid profile and weight in patients with epilepsy: a systematic review with meta-analysis.","volume":"39","author":"Chocho\u0142","year":"2025","journal-title":"CNS Drugs"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review.","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4088\/JCP.v67n0212","article-title":"A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults.","volume":"67","author":"Merideth","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1528-1157.2001.34699.x","article-title":"The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.","volume":"42","author":"Isoj\u00e4rvi","year":"2001","journal-title":"Epilepsia"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.seizure.2024.08.003","article-title":"Is there any concern of insulin resistance and metabolic dysfunctions with antiseizure medications? A prospective comparative study of valproate vs. levetiracetam.","volume":"121","author":"Sarangi","year":"2024","journal-title":"Seizure"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"704145","DOI":"10.3389\/fcvm.2021.704145","article-title":"Impact of metabolic syndrome and it\u2019s components on prognosis in patients with cardiovascular diseases: a meta-analysis.","volume":"8","author":"Li","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0895-3988(10)60037-2","article-title":"Relationship of body mass index, waist circumference and cardiovascular risk factors in Chinese adult.","volume":"23","author":"Du","year":"2010","journal-title":"Biomed Environ Sci"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1253\/circj.CJ-09-0422","article-title":"Impact of blood pressure and other components of the metabolic syndrome on the development of cardiovascular disease.","volume":"74","author":"Kang","year":"2010","journal-title":"Circ J"},{"key":"R38-20260917","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4070\/kcj.2021.0328","article-title":"Lifestyle modification in the management of metabolic syndrome: statement from Korean Society of CardioMetabolic Syndrome (KSCMS).","volume":"52","author":"Kim","year":"2022","journal-title":"Korean Circ J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:45Z","timestamp":1789624905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":36,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050264","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2026-02-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}